Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)

NCT01329471 | Unknown DMC

• 1 other identifier: HYMC-16-2011
• Study Type: observational
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to elucidate the role of RUNX1 in Acute Myeloid Leukemia (AML), in particular, the transcriptional regulation of genes by mutated forms of this protein. This research will study the effect of mutations found in AML patients

Conditions

Acute Myeloid Leukemia

Outcome Measures

Primary Outcomes (1)

• Performance of expression arrays on transfected CD34+ cells

  Performance of expression arrays on transfected CD34+ cells (derived from human cord blood), expecting differential gene expression between the wild type RUNX1-transfected cells and mutated RUNX1-transfected cells.

  One year

Study Arms (1)

Umbilical cord blood

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Female hospital patients

You may qualify if:

• Consenting women who have had full-term birth

You may not qualify if:

• Systemic disease

Sponsors & Collaborators

• Hillel Yaffe Medical Center: lead
• Weizmann Institute of Science: collaborator

Study Sites (1)

Hillel Yaffe Medical Center

Hadera, 38100, Israel

Location

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV

Study Record Dates

• First Submitted: March 10, 2011
• First Posted: April 6, 2011
• Study Start: April 1, 2011
• Primary Completion: April 1, 2012
• Study Completion: April 1, 2013
• Last Updated: April 6, 2011

Record last verified: 2011-04

Locations

IL (1)